Business Wire

CA-VELO3D

24.8.2021 15:34:09 CEST | Business Wire | Press release

Share
Velo3D Expands Team in Europe to Support Growing Demand for Industrial Metal Additive Manufacturing

As global demand for top-quality 3D-printed industrial parts continues to grow, California-based Velo3D, Inc. , a leader in advanced additive manufacturing (AM) for high-value metal parts, has announced the appointment of two new Europe-based senior executives.

Managing Director, Dr. Jose Greses , will be based between Germany and Spain while Sales Director, Xavier Fruh , will be located in France. They join Jon Porter , who was appointed earlier this year as European Business Development Director based in the U.K.

Dr. Greses holds a Ph.D. in laser welding from the University of Cambridge (U.K.) and a M.Sc. in Marine Technology from Cranfield University (U.K.). He has worked for a number of leading European manufacturing companies in laser welding and 3D-printing—most recently with GF Machining Solutions and, prior to that, for 14 years with German AM company EOS.

"Our goal is to help industries solve their engineering challenges by delivering unprecedented design freedom, part repeatability and quality in metal 3D printing," says Dr. Greses. "We're here to provide the European markets with a seamless transition to Velo3D's end-to-end manufacturing solution including its advanced support-free technology."

Xavier Fruh has a Master's degree in electrical engineering from ESIGELEC Rouen and an M.B.A. from the Strasbourg School of Management, both in France. He has years of experience in the welding industry and most recently did business development around Europe for four years with AddUp, a French group specializing in AM technology.

"I am passionate about innovation and technology," Fruh says. "I'm keen to support our customers in overcoming the limits of traditional manufacturing and to help them take advantage of everything that AM, the next generation of manufacturing engineering, has to offer."

Benny Buller , founder and CEO of Velo3D, views his company's European growth as a sign of greater awareness of the production metrics delivered by advanced 3D-printing systems. "Expanding our footprint in Europe comes in response to new demand for the very highest-achievable levels of metal AM quality that only Velo3D provides--as well as design freedom that can unleash innovation and improve competitiveness for industries such as aerospace, oil and gas, and alternative energy," he says.

In March, Velo3D announced plans to merge with JAWS Spitfire Acquisition Corporation (NYSE: SPFR ) and become a public company.

To learn more about how Velo3D empowers engineers and designers to imagine more and additively manufacture nearly anything, follow Velo3D on LinkedIn or visit velo3d.com .

About Velo3D

Velo3D, one of Fast Company’s 2021 World’s Most Innovative Companies , empowers engineers and designers to imagine more and additively manufacture nearly anything with a fully-integrated patented solution of software, hardware, and process-control featuring FlowTM print preparation software, AssureTM quality assurance software and the Sapphire® family of laser powder bed 3D printers. Velo3D additive manufacturing solutions for 3D-printing high-value metal parts allow for previously impossible geometries, so businesses can make the mission-critical parts they need without compromise. Customers include some of the world’s most visionary companies, such as Aerojet Rocketdyne, Chromalloy, Honeywell, LAM Research and Raytheon Technologies. For more information, follow Velo3D on LinkedIn or visit velo3d.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye